Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23950202 | 0.84 | MAPT (0.50) | KMT2ATDP1RAB9AUBE2NMAPT | |
| SCHEMBL23950404 | 0.77 | NLRP3 (0.54) | KMT2ATDP1TSHRUBE2NMAPT | |
| SCHEMBL23950187 | 0.77 | POLB (0.46) | KMT2AUBE2NMEN1POLB | |
| SCHEMBL23950380 | 0.75 | POLB (0.44) | KMT2ATDP1TSHRNPC1RAB9A | |
| SCHEMBL23950418 | 0.75 | NLRP3 (0.43) | KMT2ATDP1UBE2NMEN1POLB | |
| SCHEMBL23950468 | 0.74 | NLRP3 (0.60) | TSHRMAPTMAPK1ALDH1A1 | |
| SCHEMBL25753079 | 0.74 | NLRP3 (0.45) | KMT2AUBE2NPOLBTP53 | |
| SCHEMBL25753105 | 0.74 | NLRP3 (0.44) | KMT2ATDP1UBE2NMEN1POLB | |
| SCHEMBL23950842 | 0.73 | NLRP3 (0.45) | KMT2ATDP1UBE2NMEN1POLB | |
| SCHEMBL25753044 | 0.73 | THRB (0.47) | KMT2ATDP1NPC1RAB9AUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | KMT2A 3325/4885TDP1 944/4885TSHR 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.